PPARG and type 1 diabetes mellitus: Recent studies showed that PPARγ was decreased in elderly AF patients [36] and hypertensive AF patients [37], while PPARγ agonists could inhibit atrial remodeling in AF models [38, 39] and prevent new onset AF in patients with non-insulin dependent diabetes [40].